{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:00:51Z","timestamp":1780372851586,"version":"3.54.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T00:00:00Z","timestamp":1492646400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s11886-017-0855-9","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T05:57:34Z","timestamp":1492667854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Genetics of Dyslipidemia and Ischemic Heart Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Kavita","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragavendra R.","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,20]]},"reference":[{"issue":"9438","key":"855_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"\u2022\u2022 Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352. This global study has identified 9 easily measured risk factors (smoking, lipids, hypertension, diabetes, obesity, diet, physical activity, alcohol consumption, and psychosocial factors) that account for over 90% of the risk of acute myocardial infarction (AMI).","journal-title":"Lancet"},{"issue":"1","key":"855_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mcna.2012.01.001","volume":"96","author":"RR Baliga","year":"2012","unstructured":"\u2022 Baliga RR. HDL-cholesterol: perfection is the enemy of good? Med Clin North Am. 2012;96(1):27\u201337. Review discusses role of HDL-cholesterol as a risk factor for coronary artery disease","journal-title":"Med Clin North Am"},{"key":"855_CR3","doi-asserted-by":"crossref","unstructured":"Carlberg C, Ulven SM, Moln\u00e1r F, eds. Hypertension, atherosclerosis and dyslipidemia, In Nutrigenomics. New York, NY: Springer Berlin Heidelberg; 2016:195\u2013208.","DOI":"10.1007\/978-3-319-30415-1_11"},{"issue":"3 Suppl","key":"855_CR4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on familial hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S1\u20138.","journal-title":"J Clin Lipidol"},{"issue":"45","key":"855_CR5","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"\u2022\u2022 Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J. 2013;34(45):3478\u201390a. This consensus statement provides guidance for clinicians to prevent coronary heart disease in patients with familial hypercholesterolaemia.","journal-title":"Eur Heart J"},{"issue":"2","key":"855_CR6","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jacl.2014.01.002","volume":"8","author":"GF Watts","year":"2014","unstructured":"\u2022\u2022 Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the international FH foundation. J Clin Lipidol. 2014;8(2):148\u201372. Perspective on management of familial hypercholesterolemia.","journal-title":"J Clin Lipidol"},{"key":"855_CR7","doi-asserted-by":"publisher","unstructured":"Cicero AFG, ed. Clinical case 3: patient with essential hypertension and familial hypercholesterolaemia. In Hypertension and Metabolic Cardiovascular Risk Factors. Series Title: Practical Case Studies in Hypertension Management. Springer International Publishing Switzerland; 2016:33\u201350. DOI 10.1007\/978-3-319-39504-3_3","DOI":"10.1007\/978-3-319-39504-3_3"},{"issue":"4","key":"855_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"JL Goldstein","year":"2009","unstructured":"Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29(4):431\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"855_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jpeds.2009.02.022","volume":"155","author":"O Guardamagna","year":"2009","unstructured":"Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr. 2009;155(2):199\u2013204. e2","journal-title":"J Pediatr"},{"key":"855_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.ge.24.120190.001025","volume":"24","author":"HH Hobbs","year":"1990","unstructured":"Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133\u201370.","journal-title":"Annu Rev Genet"},{"issue":"5","key":"855_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0092-8674(01)00371-3","volume":"105","author":"UM Koivisto","year":"2001","unstructured":"Koivisto UM, Hubbard AL, Mellman I. A novel cellular phenotype for familial hypercholesterolemia due to a defect in polarized targeting of LDL receptor. Cell. 2001;105(5):575\u201385.","journal-title":"Cell"},{"issue":"5","key":"855_CR12","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/S0021-9258(18)34975-5","volume":"257","author":"WJ Schneider","year":"1982","unstructured":"Schneider WJ, Beisiegel U, Goldstein JL, Brown MS. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem. 1982;257(5):2664\u201373.","journal-title":"J Biol Chem"},{"issue":"3","key":"855_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/01.CIR.49.3.476","volume":"49","author":"NJ Stone","year":"1974","unstructured":"Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49(3):476\u201388.","journal-title":"Circulation"},{"issue":"2","key":"855_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00041433-200204000-00008","volume":"13","author":"AC Jansen","year":"2002","unstructured":"Jansen AC, van Wissen S, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol. 2002;13(2):165\u201371.","journal-title":"Curr Opin Lipidol"},{"issue":"21","key":"855_CR15","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1056\/NEJM199005243222104","volume":"322","author":"M Seed","year":"1990","unstructured":"\u2022\u2022 Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322(21):1494\u20139. This paper discusses role of lp(a) as a risk factor in patients with familial hypercholesterolemia.","journal-title":"N Engl J Med"},{"issue":"7293","key":"855_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bmj.322.7293.1019","volume":"322","author":"EJ Sijbrands","year":"2001","unstructured":"Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ. 2001;322(7293):1019\u201323.","journal-title":"BMJ"},{"issue":"24","key":"855_CR17","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1161\/01.CIR.0000041253.61683.08","volume":"106","author":"MA Umans-Eckenhausen","year":"2002","unstructured":"Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002;106(24):3031\u20136.","journal-title":"Circulation"},{"issue":"4","key":"855_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.mol.0000137222.23784.2a","volume":"15","author":"RP Naoumova","year":"2004","unstructured":"Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol. 2004;15(4):413\u201322.","journal-title":"Curr Opin Lipidol"},{"key":"855_CR19","unstructured":"Goldstein JLB,MS. Familal hypercholesterolemia. Berlin: Springer."},{"issue":"5","key":"855_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11886-016-0723-z","volume":"18","author":"DP Hughes","year":"2016","unstructured":"Hughes DP, Viljoen A, Wierzbicki AS. Familial hypercholesterolaemia in the era of genetic testing. Curr Cardiol Rep. 2016;18(5):42.","journal-title":"Curr Cardiol Rep"},{"issue":"19","key":"855_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","volume":"63","author":"AD Sniderman","year":"2014","unstructured":"Sniderman AD, Tsimikas S, Fazio S. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014;63(19):1935\u201347.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"855_CR22","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"\u2022\u2022 Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578\u201389. This paper discusses the utility of sequencing genes in patients with familial hypercholesterolemia.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"855_CR23","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167\u201392.","journal-title":"Circulation"},{"issue":"1","key":"855_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/ajmg.a.34368","volume":"158A","author":"JK Morris","year":"2012","unstructured":"Morris JK, Wald DS, Wald NJ. The evaluation of cascade testing for familial hypercholesterolemia. Am J Med Genet A. 2012;158A(1):78\u201384.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"855_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"DM Lloyd-Jones","year":"2016","unstructured":"\u2022\u2022 Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol. 2016;68(1):92\u2013125. This review discusses the role of non-statin therapies in the management of dyslipidemias.","journal-title":"J Am Coll Cardiol"},{"key":"855_CR26","volume-title":"Statin prescribing guide","author":"RR Baliga","year":"2010","unstructured":"\u2022 Baliga RR. Statin prescribing guide. Oxford New York: Oxford University Press; 2010. This handbook provides information on the statin therapies in dyslipidemas."},{"issue":"11","key":"855_CR27","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11936-016-0486-2","volume":"18","author":"J Parizo","year":"2016","unstructured":"Parizo J, Sarraju A, Knowles JW. Novel therapies for familial hypercholesterolemia. Curr Treat Options Cardiovasc Med. 2016;18(11):64.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"855_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11239-016-1364-1","volume":"42","author":"J Latimer","year":"2016","unstructured":"Latimer J, Batty JA, Neely RD, Kunadian V. PCSK9 inhibitors in the prevention of cardiovascular disease. J Thromb Thrombolysis. 2016;42(3):405\u201319.","journal-title":"J Thromb Thrombolysis"},{"issue":"20","key":"855_CR29","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408\u201317.","journal-title":"Circulation"},{"key":"855_CR30","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine.0(0):null."},{"issue":"32","key":"855_CR31","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European atherosclerosis society. Eur Heart J. 2014;35(32):2146\u201357.","journal-title":"Eur Heart J"},{"key":"855_CR32","volume-title":"Dyslipidemia. Oxford","author":"RR Baliga","year":"2012","unstructured":"Baliga RR, Cannon CP. Dyslipidemia. Oxford. New York: Oxford University Press; 2012."},{"issue":"3","key":"855_CR33","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ijcard.2013.06.069","volume":"168","author":"EM Ooi","year":"2013","unstructured":"Ooi EM, Barrett PH, Watts GF. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies. Int J Cardiol. 2013;168(3):1811\u20138.","journal-title":"Int J Cardiol"},{"issue":"9719","key":"855_CR34","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998\u20131006.","journal-title":"Lancet"},{"issue":"9860","key":"855_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","volume":"381","author":"M Cuchel","year":"2013","unstructured":"Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40\u20136.","journal-title":"Lancet"},{"issue":"4","key":"855_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MOL.0b013e32836308bc","volume":"24","author":"AD Marais","year":"2013","unstructured":"Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013;24(4):288\u201394.","journal-title":"Curr Opin Lipidol"},{"issue":"19","key":"855_CR37","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","volume":"128","author":"EA Stein","year":"2013","unstructured":"Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113\u201320.","journal-title":"Circulation"},{"issue":"2","key":"855_CR38","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1111\/j.1399-3046.2010.01383.x","volume":"15","author":"A Maiorana","year":"2011","unstructured":"Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant. 2011;15(2):E25\u20139.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"855_CR39","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1440-0960.2004.00103.x","volume":"45","author":"M Moyle","year":"2004","unstructured":"Moyle M, Tate B. Homozygous familial hypercholesterolaemia presenting with cutaneous xanthomas: response to liver transplantation. Australas J Dermatol. 2004;45(4):226\u20138.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"855_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273(1):6\u201330.","journal-title":"J Intern Med"},{"issue":"22","key":"855_CR41","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1001\/jama.2009.812","volume":"301","author":"G Thanassoulis","year":"2009","unstructured":"Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA. 2009;301(22):2386\u20138.","journal-title":"JAMA"},{"issue":"8","key":"855_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrendo.2016.69","volume":"12","author":"KL Ellis","year":"2016","unstructured":"Ellis KL, Hooper AJ, Burnett JR, Watts GF. Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nat Rev Endocrinol. 2016;12(8):467\u201384.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"855_CR43","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res. 2016;57(8):1339\u201359.","journal-title":"J Lipid Res"},{"issue":"26","key":"855_CR44","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"19","key":"855_CR45","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"855_CR46","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331\u20139.","journal-title":"JAMA"},{"issue":"6","key":"855_CR47","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","volume":"16","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, Kochl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16(6):713\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"855_CR48","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1172\/JCI119753","volume":"100","author":"KM Argraves","year":"1997","unstructured":"Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK. The atherogenic lipoprotein lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100(9):2170\u201381.","journal-title":"J Clin Invest"},{"issue":"5","key":"855_CR49","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/clc.4960270503","volume":"27","author":"A Deb","year":"2004","unstructured":"Deb A, Caplice NM. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27(5):258\u201364.","journal-title":"Clin Cardiol"},{"issue":"6","key":"855_CR50","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1016\/S0021-9258(19)50640-8","volume":"267","author":"ME Haberland","year":"1992","unstructured":"Haberland ME, Fless GM, Scanu AM, Fogelman AM. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 1992;267(6):4143\u201351.","journal-title":"J Biol Chem"},{"issue":"7","key":"855_CR51","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2362.1994.tb02381.x","volume":"24","author":"P Riis Hansen","year":"1994","unstructured":"Riis Hansen P, Kharazmi A, Jauhiainen M, Ehnholm C. Induction of oxygen free radical generation in human monocytes by lipoprotein(a). Eur J Clin Investig. 1994;24(7):497\u20139.","journal-title":"Eur J Clin Investig"},{"issue":"13","key":"855_CR52","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1002\/j.1460-2075.1989.tb08586.x","volume":"8","author":"EM Salonen","year":"1989","unstructured":"Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J. 1989;8(13):4035\u201340.","journal-title":"EMBO J"},{"issue":"17","key":"855_CR53","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","volume":"62","author":"JJ Albers","year":"2013","unstructured":"Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on global health outcomes). J Am Coll Cardiol. 2013;62(17):1575\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"855_CR54","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","volume":"129","author":"AV Khera","year":"2014","unstructured":"\u2022\u2022 Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation. 2014;129(6):635\u201342. This article discusses the role of lp(a) and rosuvastatin in the management of cardiovascular risk.","journal-title":"Circulation"},{"issue":"23","key":"855_CR55","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"9","key":"855_CR56","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","volume":"64","author":"P Willeit","year":"2014","unstructured":"Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck study. J Am Coll Cardiol. 2014;64(9):851\u201360.","journal-title":"J Am Coll Cardiol"},{"issue":"25 Pt B","key":"855_CR57","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"\u2022\u2022 Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934. This consensus document is a comprehensive review on the treatment of dyslipidemia to reduce the risk of coronary artery disease.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"855_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014full report. J Clin Lipidol. 2015;9(2):129\u201369.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"855_CR59","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jacl.2011.07.005","volume":"5","author":"MH Davidson","year":"2011","unstructured":"Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol. 2011;5(5):338\u201367.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"855_CR60","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jacl.2010.07.002","volume":"4","author":"WV Brown","year":"2010","unstructured":"Brown WV, Ballantyne CM, Jones PH, Marcovina S. Management of Lp(a). J Clin Lipidol. 2010;4(4):240\u20137.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"855_CR61","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MOL.0000000000000126","volume":"25","author":"S Bos","year":"2014","unstructured":"Bos S, Yayha R, van Lennep JE. Latest developments in the treatment of lipoprotein (a). Curr Opin Lipidol. 2014;25(6):452\u201360.","journal-title":"Curr Opin Lipidol"},{"key":"855_CR62","doi-asserted-by":"publisher","unstructured":"Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and Apo(a) characterization. Arterioscler Thromb Vasc Biol 2016.","DOI":"10.1161\/ATVBAHA.116.307983"},{"issue":"6","key":"855_CR63","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/MOL.0b013e3283598d81","volume":"23","author":"B Kolski","year":"2012","unstructured":"Kolski B, Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23(6):560\u20138.","journal-title":"Curr Opin Lipidol"},{"issue":"17","key":"855_CR64","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.jacc.2013.07.023","volume":"62","author":"JR Guyton","year":"2013","unstructured":"Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013;62(17):1580\u20134.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"855_CR65","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/MOL.0000000000000090","volume":"25","author":"PJ Talmud","year":"2014","unstructured":"Talmud PJ, Futema M, Humphries SE. The genetic architecture of the familial hyperlipidaemia syndromes: rare mutations and common variants in multiple genes. Curr Opin Lipidol. 2014;25(4):274\u201381.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"855_CR66","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2004-0432","volume":"89","author":"MC Carr","year":"2004","unstructured":"Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab. 2004;89(6):2601\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"855_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/MOL.0000000000000270","volume":"27","author":"AJ Brahm","year":"2016","unstructured":"Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. Curr Opin Lipidol. 2016;27(2):131\u201340.","journal-title":"Curr Opin Lipidol"},{"issue":"1 Suppl","key":"855_CR68","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","volume":"10","author":"HE Bays","year":"2016","unstructured":"Bays HE, Jones PH, Orringer CE, Brown WV, Jacobson TA. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016;10(1 Suppl):S1\u201343.","journal-title":"J Clin Lipidol"},{"key":"855_CR69","unstructured":"Merkens LS, Myrie SB, Steiner RD, Mymin D. Sitosterolemia. 1993."},{"issue":"2","key":"855_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/MOL.0000000000000277","volume":"27","author":"JM Jeff","year":"2016","unstructured":"Jeff JM, Peloso GM, Do R. What can we learn about lipoprotein metabolism and coronary heart disease from studying rare variants? Curr Opin Lipidol. 2016;27(2):99\u2013104.","journal-title":"Curr Opin Lipidol"},{"issue":"2","key":"855_CR71","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"issue":"2","key":"855_CR72","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"855_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"855_CR74","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","volume":"115","author":"N Sarwar","year":"2007","unstructured":"Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115(4):450\u20138.","journal-title":"Circulation"},{"issue":"11","key":"855_CR75","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345\u201352.","journal-title":"Nat Genet"},{"issue":"4","key":"855_CR76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","volume":"61","author":"A Varbo","year":"2013","unstructured":"Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427\u201336.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0855-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0855-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T17:38:37Z","timestamp":1719164317000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0855-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,20]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0855-9","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,20]]},"article-number":"46"}}